No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TBPH Theravance Biopharma
- 8.980
- -0.140-1.54%
Close May 22 16:00 ET
- 8.890
- -0.090-1.00%
Post 16:05 ET
436.73MMarket Cap-10089P/E (TTM)
9.460High8.945Low237.25KVolume9.080Open9.120Pre Close2.17MTurnover1.55%Turnover RatioLossP/E (Static)48.63MShares11.71052wk High2.13P/B137.22MFloat Cap8.21052wk Low--Dividend TTM15.28MShs Float124.866Historical High--Div YieldTTM5.65%Amplitude6.100Historical Low9.150Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Theravance Biopharma First Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Theravance Biopharma | 10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
Theravance Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 106.61% HC Wainwright & Co. → $20 Reiterates Buy → Buy 04/12/2024 116.94% BTIG → $21 Initiates
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:Financial Performance:Theravance Biopharma reported Q1 net sales of $55.2 million in partnership wi
Comments
Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.
Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To ProfitTheravance Biopharma's high P/S ratio is alarming considering its unimpressive revenue predictions. Investors seem hopeful for a business turnaround, but analysts lack confidence. The anticipated revenue growth could pressure the share price.
The appointment of Jeremy Grant and the cooperation with Irenic are seen as positive steps towards strengthening Theravance's position. Irenic supports Theravance's potential to successfully complete the Phase 3 trial of ampreloxetine and deliver enhanced value to shareholders.
$Theravance Biopharma(TBPH.US$ Viatris And Theravance Biopharma Announce Top-Line Results From Yupelri Phase III Trial In China For The Treatment Of Chronic Obstructive Pulmonary Disease
Moomoo 24/7· 3 mins ago
Moomoo 24/7· 3 mins ago
The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg